- Home
- IMNM vs STK Comparison
IMNM vs STK Comparison
Compare IMNM & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- STK
- Stock Information
- Founded
- IMNM 2006
- STK 2009
- Country
- IMNM United States
- STK United States
- Employees
- IMNM N/A
- STK N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- STK Investment Managers
- Sector
- IMNM Health Care
- STK Finance
- Exchange
- IMNM Nasdaq
- STK Nasdaq
- Market Cap
- IMNM 542.6M
- STK 545.8M
- IPO Year
- IMNM 2020
- STK N/A
- Fundamental
- Price
- IMNM $7.91
- STK $26.08
- Analyst Decision
- IMNM Strong Buy
- STK
- Analyst Count
- IMNM 6
- STK 0
- Target Price
- IMNM $26.00
- STK N/A
- AVG Volume (30 Days)
- IMNM 1.7M
- STK 38.2K
- Earning Date
- IMNM 05-13-2025
- STK 01-01-0001
- Dividend Yield
- IMNM N/A
- STK 6.60%
- EPS Growth
- IMNM N/A
- STK N/A
- EPS
- IMNM N/A
- STK N/A
- Revenue
- IMNM $9,041,000.00
- STK N/A
- Revenue This Year
- IMNM N/A
- STK N/A
- Revenue Next Year
- IMNM $1,259.12
- STK N/A
- P/E Ratio
- IMNM N/A
- STK N/A
- Revenue Growth
- IMNM N/A
- STK N/A
- 52 Week Low
- IMNM $5.15
- STK $24.95
- 52 Week High
- IMNM $19.07
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- IMNM 55.28
- STK 37.04
- Support Level
- IMNM $6.96
- STK $25.84
- Resistance Level
- IMNM $7.56
- STK $27.55
- Average True Range (ATR)
- IMNM 0.69
- STK 1.12
- MACD
- IMNM 0.26
- STK 0.07
- Stochastic Oscillator
- IMNM 98.22
- STK 55.80
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.